Khang & Khang LLP announces that it is investigating claims of potential
misrepresentations by Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s” or
the “Company”) (NYSE: RDY). The investigation focuses on whether the
Company and its officers violated securities laws by issuing misleading
information to investors.
If you purchased shares of Dr. Reddy’s during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by
email at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
On November 6, 2015, the Company announced that it received a warning
letter from the U.S. Food and Drug Administration over inadequate
quality control procedures at three manufacturing plants in India. When
the truth was revealed, shares dropped causing investors harm.
If you wish to learn more about this lawsuit, or if you have any
questions concerning this notice or your rights, please contact Joon M.
Khang, a prominent litigator for almost two decades, by telephone: (949)
419-3834, or by email at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151111006229/en/
Copyright Business Wire 2015